United States · Bill · S
S. 288 (117th)
TRANSPLANT Act of 2021
Introduced
8 February 2021
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S575)
Sponsors
—
Subjects
Discovery layer
Source updated
5 December 2025
Summary
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021 or the TRANSPLANT Act of 2021 This bill modifies and reauthorizes through FY2026 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments. In addition, the Government Accountability Office must report on the regenerative medicine workforce.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 8 February 2021
Introduced in Senate (PDF)
Introduced in Senate · EN · 8 February 2021
Introduced in Senate
summary · EN · 8 February 2021
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/288
- Open data entity: https://api.congress.gov/v3/bill/117/s/288